Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial

The Lancet

Volumn 387, Issue 10018, 2016, Pages 545-557

  Wang Gillam, Andrea ^a   Li, Chung Pin ^b   Bodoky, György ^c   Dean, Andrew ^d   Shan, Yan Shen ^f   Jameson, Gayle ^g   MacArulla, Teresa ^h   Lee, Kyung Hun ⁱ   Cunningham, David ^j   Blanc, Jean F ^k   Hubner, Richard A ^l   Chiu, Chang Fang ^m   Schwartsmann, Gilberto ⁿ   Siveke, Jens T ^o   Braiteh, Fadi ^p   Moyo, Victor ^q   Belanger, Bruce ^q   Dhindsa, Navreet ^q   Bayever, Eliel ^q   Von Hoff, Daniel D ^g   Chen, Li Tzong ^e,f   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c St László Teaching Hospital   (Hungary)

^d ST JOHN OF GOD HOSPITAL   (Australia)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g Virginia G Piper Cancer Center   (United States)

^h VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

ⁱ Seoul National University Hospital   (South Korea)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k HÔPITAL SAINT ANDRÉ   (France)

^l CHRISTIE HOSPITAL   (United Kingdom)

^m CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁿ HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^p Department of Hematology Oncology   (United States)

^q MERRIMACK PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LIPOSOME; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CAUSE OF DEATH; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROCOLITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEALTH STATUS; HUMAN; HYPOKALEMIA; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTATIC PANCREATIC CANCER; METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA; MONOTHERAPY; MORTALITY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; TIME TO TREATMENT; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; CHEMICALLY INDUCED; CLINICAL TRIAL; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DIARRHEA; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 84959459386     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00986-1     Document Type: Article

References (29)

1. American Cancer Society Cancer facts and figures, 2015 2015 American Cancer Society Atlanta
2. National Comprehensive Cancer Network NCCN guidelines for treatment of cancer by site: pancreatic adenocarcinoma (version 2) 2015 National Comprehensive Cancer Network Fort Washington
3. HA Burris 3rd, MJ Moore, J Andersen et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
4. AM Storniolo, NH Enas, CA Brown, M Voi, ML Rothenberg, R Schilsky An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma Cancer 85 1999 1261 1268
5. MJ Moore, D Goldstein, J Hamm et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966
6. T Conroy, F Desseigne, M Ychou for the Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
7. DD Von Hoff, T Ervin, FP Arena et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 2013 1691 1703
8. EJ Walker, AH Ko Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol 20 2014 2224 2236
9. SY Yi, YS Park, HS Kim et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer Cancer Chemother Pharmacol 63 2009 1141 1145
10. C Yoo, JY Hwang, JE Kim et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer Br J Cancer 101 2009 1658 1663
11. V Gebbia, E Maiello, F Giuliani, N Borsellino, C Arcara, G Colucci Irinotecan plus bolus/infusional 5-fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale Am J Clin Oncol 33 2010 461 464
12. S Cereda, M Reni, A Rognone et al. XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer Anticancer Res 30 2010 4785 4790
13. A Zaniboni, E Aitini, S Barni et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study Cancer Chemother Pharmacol 69 2012 1641 1645
14. C Neuzillet, O Hentic, B Rousseau et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts World J Gastroenterol 18 2012 4533 4541
15. E Assaf, M Verlinde-Carvalho, C Delbaldo et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma Oncology 80 2011 301 306
16. M Cantore, C Rabbi, G Fiorentini et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer Oncology 67 2004 93 97
17. SY Oh, HJ Kim, TH Kim et al. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer Invest New Drugs 28 2010 343 349
18. H Ulrich-Pur, M Raderer, G Verena Kornek et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma Br J Cancer 88 2003 1180 1184
19. M Reni, MG Panucci, P Passoni et al. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial Cancer Invest 22 2004 688 696
20. AH Ko, E Dito, B Schillinger, AP Venook, EK Bergsland, MA Tempero Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study Cancer Invest 26 2008 47 52
21. AV Kalra, J Kim, SG Klinz et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion Cancer Res 74 2014 7003 7013
22. AC Roy, SR Park, D Cunningham et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma Ann Oncol 24 2013 1567 1573
23. Ramanathan RK, Korn RL, Sachdev JC, et al. Lesion characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation with treatment response to MM-398, nanoliposomal irinotecan (nal-IRI). 26th EORTC-NCI-AACR Symposium; Barcelona, Spain; Nov 18-21, 2014. Abstract 261.
24. AH Ko, MA Tempero, YS Shan et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, nal-IRI) for patients with gemcitabine-refractory metastatic pancreatic cancer Br J Cancer 109 2013 920 925
25. B Chibaudel, F Maindrault-Goebel, T Andre et al. PEPCOL: a randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer - a GERCOR study Proc Am Soc Clin Oncol 33 suppl 3 2015 abstr 751.
26. TC Chang, HS Shiah, CH Yang et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients Cancer Chemother Pharmacol 75 2015 579 586
27. NF Smith, WD Figg, A Sparreboom Pharmacogenetics of irinotecan metabolism and transport: an update Toxicol In Vitro 20 2006 163 175
28. H Oettle, H Riess, JM Stieler et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial J Clin Oncol 32 2014 2423 2429
29. S Gill, Y-J Ko, MC Cripps et al. PANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT) Proc Am Soc Clin Oncol 32 suppl 5 2014 abstr 4022.